Supplementary Table 4. Lipoprotein triglycerides by lipoprotein subclass measured using gel-permeation high-performance liquid chromatography.
| Subclass | IR 0.2 mg/day | XR 0.2 mg/day | XR 0.4 mg/day | |
|---|---|---|---|---|
| Chylomicron | N | 115 | 115 | 118 |
| Baseline, mg/dL | 54.9±59.8 | 51.3±46.0 | 49.6±42.0 | |
| Percentage change, % | -58.4 [-71.4, -45.5] | -42.8 [-55.7, -29.9] | -50.6 [-63.4, -37.9] | |
| p value vs IR 0.2 mg/day | 0.094 | 0.397 | ||
| Large VLDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 186.3±82.5 | 169.3±60.5 | 179.8±68.5 | |
| Percentage change, % | -42.5 [-48.0, -37.0] | -34.8 [-40.3, -29.3] | -45.0 [-50.4, -39.7] | |
| p value vs IR 0.2 mg/day | 0.051 | 0.520 | ||
| Medium VLDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 30.0±10.8 | 27.2±7.9 | 29.4±10.4 | |
| Percentage change, % | -37.3 [-41.0, -33.6] | -35.3 [-38.9, -31.6] | -39.1 [-42.7, -35.5] | |
| p value vs IR 0.2 mg/day | 0.439 | 0.496 | ||
| Small VLDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 10.5±3.3 | 9.7±2.7 | 10.2±3.2 | |
| Percentage change, % | -21.2 [-24.4, -18.1] | -21.4 [-24.5, -18.2] | -19.8 [-22.9, -16.7] | |
| p value vs IR 0.2 mg/day | 0.953 | 0.522 | ||
| Large LDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 13.0±3.5 | 12.3±3.4 | 12.7±3.6 | |
| Percentage change, % | -6.2 [-9.6, -2.8] | -5.4 [-8.8, -2.0] | 0.5 [-2.9, 3.9] | |
| p value vs IR 0.2 mg/day | 0.729 | 0.006 | ||
| Medium LDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 13.3±3.5 | 12.9±3.8 | 13.0±3.4 | |
| Percentage change, % | -10.8 [-14.0, -7.7] | -9.3 [-12.5, -6.2] | -4.2 [-7.3, -1.1] | |
| p value vs IR 0.2 mg/day | 0.497 | 0.003 | ||
| Small LDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 7.1±2.5 | 6.9±2.3 | 6.9±2.3 | |
| Percentage change, % | -32.4 [-35.8, -29.1] | -30.2 [-33.5, -26.8] | -29.4 [-32.7, -26.1] | |
| p value vs IR 0.2 mg/day | 0.349 | 0.202 | ||
| Very small LDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 4.3±2.4 | 4.0±1.8 | 4.1±1.9 | |
| Percentage change, % | -43.8 [-48.0, -39.6] | -38.5 [-42.7, -34.3] | -41.7 [-45.9, -37.6] | |
| p value vs IR 0.2 mg/day | 0.078 | 0.490 | ||
| Very large HDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 1.8±1.4 | 1.6±1.0 | 1.6±0.9 | |
| Percentage change, % | -44.9 [-50.5, -39.3] | -37.3 [-42.9, -31.7] | -45.2 [-50.7, -39.8] | |
| p value vs IR 0.2 mg/day | 0.060 | 0.926 | ||
| Large HDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 4.0±3.9 | 3.4±2.3 | 3.6±2.1 | |
| Percentage change, % | -47.3 [-52.6, -42.1] | -41.0 [-46.3, -35.7] | -52.3 [-57.5, -47.1] | |
| p value vs IR 0.2 mg/day | 0.097 | 0.19 | ||
| Medium HDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 7.9±3.9 | 7.5±2.9 | 7.7±3.0 | |
| Percentage change, % | -23.4 [-27.7, -19.0] | -16.4 [-20.7, -12.1] | -22.7 [-26.9, -18.4] | |
| p value vs IR 0.2 mg/day | 0.026 | 0.828 | ||
| Small HDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 5.7±2.0 | 5.6±1.9 | 5.6±1.8 | |
| Percentage change, % | -20.7 [-25.0, -16.3] | -14.2 [-18.6, -9.8] | -17.2 [-21.5, -12.8] | |
| p value vs IR 0.2 mg/day | 0.041 | 0.265 | ||
| Very small HDL | N | 115 | 115 | 118 |
| Baseline, mg/dL | 2.9±1.2 | 2.8±1.0 | 2.8±1.0 | |
| Percentage change, % | -27.4 [-31.3, -23.5] | -20.9 [-24.8, -17.1] | -25.9 [-29.7, -22.1] | |
| p value vs IR 0.2 mg/day | 0.022 | 0.591 |
N indicates the number of patients in the full analysis set. Baseline levels are presented as mean±standard deviation. Percentage changes are presented as least-squares mean [95% confidence interval], estimated using ANCOVA at week 12, providing p-values vs. IR 0.2 mg/day.
HDL, high-density lipoproteins; IR 0.2 mg/day, pemafibrate immediate-release tablets 0.2 mg/day (twice daily); LDL, low-density lipoproteins; VLDL, very low-density lipoproteins; XR 0.2 mg/day, pemafibrate extended-release tablets 0.2 mg/day (once daily); XR 0.4 mg/day, pemafibrate extended-release tablets 0.4 mg/day (once daily).